drugset / Trial / NCT06439485
Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion
Phase 1/2
Recruiting
25 enrolled
M.D. Anderson Cancer Center
Genentech, Inc. · collabIncyte Corporation · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To learn if pemigatinib in combination with atezolizumab and bevacizumab can help to control cholangiocarcinoma.
Timeline
- Start
- 2024-11-19
- Primary completion
- 2028-02-22
- Completion
- 2030-02-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | — | Oral |
| Subject | Bevacizumab | Monoclonal antibody | — | Oral |
| Subject | Pemigatinib | Small molecule | — | Oral |